Production and Evaluation of Specific Single-Chain Antibodies against CTLA-۴ for Cancer-Targeted Therapy

  • سال انتشار: 1396
  • محل انتشار: مجله گزارش های بیوشیمی و زیست شناسی مولکولی، دوره: 6، شماره: 1
  • کد COI اختصاصی: JR_RBMB-6-1_002
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 148
دانلود فایل این مقاله

نویسندگان

Farideh Hosseinzadeh

Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran-Recombinant antibody laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran

Saeed Mohammadi

Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran-Recombinant antibody laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran

Foroogh Nejatollahi

Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran-Recombinant antibody laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran

چکیده

Background:  Cytotoxic T lymphocyte–associated antigen ۴ (CTLA-۴) molecules are expressed on T-cells and inhibit their function by inhibiting activation of subsequent T-cell molecular pathways. Blocking of CTLA-۴ inhibits the growth of malignant tumor cells. Anti-CTLA-۴ monoclonal antibodies activate the immune system against cancer. Due to several advantages of single-chain antibodies (scFvs) compared to monoclonal antibodies in cancer immunotherapy, specific anti-CTLA-۴ scFvs (single-chain variable fragment) were selected in this study. Methods: A phage antibody display library of scFvs was analyzed and a panning process was performed against an immunodominant epitope of CTLA-۴. PCR and DNA fingerprinting were used to differentiate the specific clones. The specificity of the selected clones was investigated by phage ELISA (Enzyme-linked immunosorbent assay). Results: Two specific clones with frequencies of ۳۵ and ۲۰% were identified. The clones reacted with the corresponding epitope on ELISA, while no reactivity was observed with an unrelated peptide, M۱۳KO۷ helper phage, unrelated scFvs, or no peptide as negative controls. Conclusions: Targeted therapy against cancer markers is an ideal treatment strategy. Specific human anti-CTLA-۴scFvs were selected in this study. These scFvs bound the related epitope. These antibodies have the potential to be used for targeted therapy, where the blocking of CTLA۴ receptor is needed. The study suggests further evaluation of the selected scFvs to reveal the effects of the selected antibodies.

کلیدواژه ها

Cancer immunotherapy, CTLA-۴, ScFv antibodies

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.